The iconic rise of copyright’s flagship product presented a massive chance for shareholders , but its period has expired , creating a complex landscape. Generic versions have entered the market , eroding revenues and putting pressure on profit percentages . While major drug companies maintain a stake in this sector , the outlook looks ambiguous b